{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:25:03Z","timestamp":1767626703913},"reference-count":20,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,10,1]]},"DOI":"10.1248\/bpb.b21-00198","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T22:10:42Z","timestamp":1633039842000},"page":"1413-1418","source":"Crossref","is-referenced-by-count":4,"title":["Palonosetron &lt;i&gt;versus&lt;\/i&gt; Granisetron in Combination with Aprepitant and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy: A Single-Institutional Retrospective Cohort Study"],"prefix":"10.1248","volume":"44","author":[{"given":"Takanori","family":"Miyoshi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, National Hospital Organization Kyushu Medical Center"},{"name":"Department of Pharmacy, National Hospital Organization Beppu Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Miyashita","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Hospital Organization Beppu Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Hospital Organization Beppu Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Odawara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Hospital Organization Beppu Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minako","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Hospital Organization Beppu Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Hiraki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Hospital Organization Beppu Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Kawanaka","sequence":"additional","affiliation":[{"name":"Department of Surgery, National Hospital Organization Beppu Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, du Bois A, Tonato M. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2014an update. <i>Support. Care Cancer<\/i>, <b>13<\/b>, 80\u201384 (2005).","DOI":"10.1007\/s00520-004-0718-y"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. <i>J. Clin. Oncol.<\/i>, <b>24<\/b>, 4472\u20134478 (2006).","DOI":"10.1200\/JCO.2006.05.6382"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH. Antiemetics: ASCO guideline update. <i>J. Clin. Oncol.<\/i>, <b>38<\/b>, 2782\u20132797 (2020).","DOI":"10.1200\/JCO.20.01296"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann. Oncol.<\/i>, <b>27<\/b> (suppl. 5), v119\u2013v133 (2016).","DOI":"10.1093\/annonc\/mdw270"},{"key":"5","unstructured":"5) National Comprehensive Cancer Network. \u201cNCCN Clinical Practice Guidelines in Oncology; Antiemetics version 2. 2020.\u201d: \u2039https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf\u203a, accessed 25 October, 2020."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Takeuchi H, Saeki T, Aiba K, <i>et al.<\/i> Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. <i>Int. J. Clin. Oncol.<\/i>, <b>21<\/b>, 1\u201312 (2016).","DOI":"10.1007\/s10147-015-0852-1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Matsui R, Suzuki K, Takiguchi T, Nishio M, Koike T, Hayashi T, Seto T, Kogure Y, Nogami N, Fujiwara K, Kaneda H, Harada T, Shimizu S, Kimura M, Kenmotsu H, Shimokawa M, Goto K. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study. <i>BMC Pharmacol. Toxicol.<\/i>, <b>21<\/b>, 72 (2020).","DOI":"10.1186\/s40360-020-00445-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T, Ogawa S, Sakai K, Ichinoe A, Ueoka Y, Hasuo Y, Nishida M, Masuda S, Kato K. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. <i>Int. J. Clin. Oncol.<\/i>, <b>21<\/b>, 491\u2013497 (2016).","DOI":"10.1007\/s10147-015-0928-y"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Rojas C, Raje M, Tsukamoto T, Slusher BS. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. <i>Eur. J. Pharmacol.<\/i>, <b>722<\/b>, 26\u201337 (2014).","DOI":"10.1016\/j.ejphar.2013.08.049"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. <i>Ann. Oncol.<\/i>, <b>14<\/b>, 1570\u20131577 (2003).","DOI":"10.1093\/annonc\/mdg417"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial <i>versus<\/i> dolasetron. <i>Cancer<\/i>, <b>98<\/b>, 2473\u20132482 (2003).","DOI":"10.1002\/cncr.11817"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Fujiwara S, Terai Y, Tsunetoh S, Sasaki H, Kanemura M, Ohmichi M. Palonosetron <i>versus<\/i> granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer. <i>J. Gynecol. Oncol.<\/i>, <b>26<\/b>, 311\u2013319 (2015).","DOI":"10.3802\/jgo.2015.26.4.311"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Hayashi T, Shimokawa M, Matsuo K, Iihara H, Kawada K, Nakano T, Egawa T. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis. <i>BMC Cancer<\/i>, <b>21<\/b>, 74 (2021).","DOI":"10.1186\/s12885-021-07802-y"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. <i>Bone Marrow Transplant.<\/i>, <b>48<\/b>, 452\u2013458 (2013).","DOI":"10.1038\/bmt.2012.244"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Aapro M, Molassiotis A, Dicato M, Pelaez I, Rodriguez-Lescure A, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). <i>Ann. Oncol.<\/i>, <b>23<\/b>, 1986\u20131992 (2012).","DOI":"10.1093\/annonc\/mds021"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Hesketh PJ, Aapro M, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. <i>Support. Care Cancer<\/i>, <b>18<\/b>, 1171\u20131177 (2010).","DOI":"10.1007\/s00520-009-0737-9"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Warr DG, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. <i>Support. Care Cancer<\/i>, <b>19<\/b>, 807\u2013813 (2011).","DOI":"10.1007\/s00520-010-0899-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. <i>Support. Care Cancer<\/i>, <b>20<\/b>, 107\u2013117 (2012).","DOI":"10.1007\/s00520-010-1073-9"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Mosa ASM, Hossain AM, Lavoie BJ, Yoo I. Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review. <i>Front. Pharmacol.<\/i>, <b>11<\/b>, 329 (2020).","DOI":"10.3389\/fphar.2020.00329"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Shimizu H, Suzuki K, Uchikura T, Tsuji D, Yamanaka T, Hashimoto H, Goto K, Matsui R, Seki N, Shimada T, Ikeda S, Ikegami N, Hama T, Yamamoto N, Sasaki T. Economic analysis of palonosetron <i>versus<\/i> granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial). <i>J. Pharm. Health Care Sci.<\/i>, <b>4<\/b>, 31 (2018).","DOI":"10.1186\/s40780-018-0128-9"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/10\/44_b21-00198\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T04:37:38Z","timestamp":1715143058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/10\/44_b21-00198\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b21-00198","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]},"article-number":"b21-00198"}}